Diabetic nephropathy occurs in approximately one-third
of all people with diabetes and is the leading cause of renal
failure in developed and developing countries. Angiotensin
II plays a potent role in the initiation and progression of
diabetic nephropathy by increasing glmoerular pressure and
glmoerular selectivity as well as activation of fibrosis and
cellular growth in the kidney. Thus, agents which can inhibit
the formation of angiotensin-II like ACE inhibitors or agents
that can block the action of angiotensin II such as ATI recptor
blockers have potential role in prevention of diabetic nephropathy.
This study was designed to evaluate and compare the
reno protective effects of (ACEI) perindorpil and (ARB)
telmisartan on rats with diabetic nephropathy.
Diabetic nephropathy was induced in rats by streptozotocin
(STZ) 100mg/Kg/single I.P administration. Diabetic nephropathy
rats were randomly divided into 3 groups. Diabetic
nephropathy group, perindopril ((In/kg/day) and telmisartan
group (!Ding/kg/day). Each drug was given orally for 8 weeks
stating with STZ injection. Fasting blood glucose (FBG),
advanced glycation end products (AGEPs). blood urea, serum
creatinine, urine protein, tissue malondyaldehyde (MDA)
and tissue reduced glutathione (RG) were measured by colorimetric
methods. Renal tissue specimens were histopathologically
examined by hematoxylin & eosin staining (H & E).
Both drugs significantly reduced FBG, AGEPs, blood
urea, serum creatinine, urine proteins, tissue MDA and significantly
increased tissue RG. Moreover, histopahtological
examination of kidney tissues showed improvement of nephropathy
in the form of reduction of thickening and infiltration
of the infalammatory cells with more superior effects of
telmisartan over perindopril. |
